Rodolfo Do Couto Maia
Research Subjects
Rodolfo Do Couto Maia has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Eliezer Jesus Barreiro
Universidade Federal do Rio de Janeiro
3 shared publications - Lucas Silva Franco
Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
2 shared publications - Ana Luísa Palhares Miranda
Universidade Federal do Rio de Janeiro, Brasil
1 shared publication - Antonio Carlos Doriguetto
Laboratório de Cristalografia, Universidade Federal de Alfenas, Alfenas, Brazil
1 shared publication - Carlos Alberto Manssour Fraga
Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Cidade Universitária, Rio de Janeiro 21941-902, Brazil
1 shared publication - Carlos Maurício Rabello Sant'ANna
Universidade Federal Rural do Rio de Janeiro
1 shared publication
Latest Publications
- Open Access
- 6 June 2026
- Published by Springer Nature in Chemical Papers
- Vol. 80 (10) , 12023-12040
Chimeric 3D model of EGFR and VEGFR-2 for the discovery of dual inhibitors
- 6 June 2026
- Published by Springer Nature in Chemical Papers
- Vol. 80 (10) , 12023-12040
Open AccessChimeric 3D model of EGFR and VEGFR-2 for the discovery of dual inhibitors
- 2 November 2020
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 12 (1) , 110-119
Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (MPRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model
A SARS-CoV-2 main protease (MPRO) inhibitor was discovered employing molecular docking and a fragment-based pharmacophore model as virtual screening strategies.
- 2 November 2020
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 12 (1) , 110-119
Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (MPRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model
A SARS-CoV-2 main protease (MPRO) inhibitor was discovered employing molecular docking and a fragment-based pharmacophore model as virtual screening strategies.
- 6 June 2018
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 9 (8) , 1273-1281
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
Novel SGLT-2 selective inhibitors, an innovative therapeutic approach for glycemia control in diabetic patients.
- 6 June 2018
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 9 (8) , 1273-1281
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
Novel SGLT-2 selective inhibitors, an innovative therapeutic approach for glycemia control in diabetic patients.
- 1 September 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (18) , 6517-6525
Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: Discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole
- 1 September 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 17 (18) , 6517-6525
Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: Discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole